Skip to content
Home/Companies/Biotech/OXGENE
OX

OXGENE

Biotech·UK·Exited 2021·Held 6yr

OXGENE is a biotech company, headquartered in UK.

Entry
2015
Hold
6yr
Exit
2021
Est. EV
–

Who owns OXGENE?

OXGENE was owned by Mercia Asset Management through Mercia Direct Investments (2014 vintage) from 2015 to 2021, exited via Trade Sale.

Hand-verified · updated 2026-06-01

Mercia Asset Management
Investor
Mercia Asset Management
Mercia Direct Investments · 2014 · Balance Sheet

Key facts

HQUK
SectorBiotech
StatusAcquired
Exit Type
Trade Sale
Buyer
–
MOIC
–
Exit Year
2021

More from Mercia Direct Investments

Other portfolio companies in the same fund.

Axis Spine Technologies
Active
MedTechUK· 2022
Netacea
Active
CybersecurityUK· 2022
Nova Pangaea
Active
ClimateTechUK· 2022
Locate Bio
Active
BiotechUK· 2021
Pimberly
Active
SaaSUK· 2021
Clear Review
Exited 2020
HR TechUK· 2019
to

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings